Double-Blind, Placebo-Controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients With Perennial Allergic Rhinoconjunctivitis.

Trial Profile

Double-Blind, Placebo-Controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients With Perennial Allergic Rhinoconjunctivitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2012

At a glance

  • Drugs CMP 001 (Primary)
  • Indications Hypersensitivity; Rhinoconjunctivitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 13 Jan 2009 Results from a subgroup analysis of patients with allergic asthma (52 out of 80 patients) have been reported in a Cytos Biotechnology media release; data from allergy diary entries were also reported.
    • 13 Jan 2009 Results have been presented at the 2008 meeting of American College of Allergy, Asthma and Immunology according to a Cytos Biotechnology media release.
    • 10 Jul 2008 Status changed from in progress to completed, based on results data reported in a Cytos media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top